Influence of metals on rhinosinusal polyposis in Sardinian population (Italy)

Asara, Yolande; Melis, Andrea; Luca, Laura Maria De; Bozzo, Corrado; Castiglia, Paolo; Chessa, Giannina; Piras, P; Karligkiotis, Apostolos; Bandiera, Pasquale; Malaguarnera, Michele; Marchal, Juan Antonio; Madeddu, Roberto

doi:10.1007/s11356-016-7406-6

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, they are being tested several mutated c-Kit inhibitors in the treatment of metastatic disease (imatinib, dasatinib, sunitinib or sorafenib) [ 107 – 112 ]. Hodi FS et al reported good response on treatment in a patient with KIT mutated rectal melanoma [ 113 ] and Minor DR et al reported a complete remission for 15 months in patients with KIT-mutated underwent to sunitinib treatment [ 114 ]. In a study a patient with mucosal melanoma that received the mTOR inhibitor everolimus constituted a partial response [ 115 ].…”

Section: Introductionmentioning

confidence: 99%

Anorectal mucosal melanoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

Anorectal melanoma is an uncommon and aggressive mucosal melanocytic malignancy. Due to its rarity, the pre-operative diagnosis remains difficult. The first symptoms are non-specific such as anal bleeding, anal mass or pain. Although anorectal melanoma carries a poor prognosis; optimal therapeutics strategies are unclear.Surgical resection remains the mainstay of treatment. The optimal surgical procedure for primary tumours is controversial and can vary from wide local excision or endoscopic mucosal resection (EMR) to an abdomino-perineal resection.A high degree of uncertainly exists regarding the benefit of radiation therapy or chemotherapy. The treatment of advanced melanoma is evolving rapidly with better understanding of the disease biology and immunology. Considerable effort has been devoted to the identification of molecular determinants of response to target therapies and immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Anorectal mucosal melanoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fact, IFN-α has been shown to increase degradation of 5-hidroxytryptamine (5-HT) and tryptophan. IFN-α also decreases mRNA levels and protein expression of 5-HT receptor 1A, resulting in down-regulation and thus lower concentration of 5HT [ 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV. Patients and Methods: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (N-acetylcysteine 600 mg and lactoferrin 23.6 g), while 30 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b, Ribavirin and association of N-acetylcysteine 600 mg, lactoferrin 23.6 g and Resveratrol 19.8 mg for 12 months. All subjects underwent laboratory exams and questionnaires to evaluate mood and sleep disorders (General Health Questionnaire (GHQ), Profile of Mood States (POMS), Pittsburgh Sleep Quality Inventory (PSQI), Epworth Sleepiness Scale (ESS)). Results: The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (p < 0.0001); after 12 months in aspartate aminotransferase (AST) (p < 0.0001) Viremia (p < 0.0001), HAI (p < 0.0012) and C-reactive protein (p < 0.0001); and at follow up in AST (p < 0.0001), Viremia (p < 0.0026) and C-reactive protein (p < 0.0001). Significant differences were observed after 12 month and follow-up in General Health Questionnaire, after 1, 6, 12 and follow-up in Profile of Mood States, after 6, 12, follow-up in Pittsburgh Sleep Quality Inventory and Epworth Sleepiness Scale. Conclusions: Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg–IFN-α and RBV.

show abstract

Influence of metals on rhinosinusal polyposis in Sardinian population (Italy)

Cited by 2 publications

References 33 publications

Anorectal mucosal melanoma

Anorectal mucosal melanoma

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance

Contact Info

Product

Resources

About